drugset / Trial / NCT03060447
Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to evaluate the safety and tolerability of a 10-dose regimen of vesatolimod in HIV-1 infected controllers on antiretroviral treatment (ART) and during analytical treatment interruption (ATI) following vesatolimod dosing.
Timeline
- Start
- 2017-05-09
- Primary completion
- 2020-02-13
- Completion
- 2020-02-13
Publications
- Results SenGupta D, Ramgopal M, Brinson C, DeJesus E, Mills A, Shalit P, et al. Safety and Analytic Treatment Interruption Outcomes of Vesatolimod in HIV Controllers. Oral Presentation at CROI 2020, Boston, USA. Abstract 3982.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vesatolimod | Small molecule | 4 mg | Oral |
| Subject | Vesatolimod | Small molecule | 8 mg | Oral |
| Background | Dolutegravir | Other / unclassified | — | — |
| Background | Maraviroc | Other / unclassified | — | — |
| Background | Raltegravir | Other / unclassified | — | — |
| Background | Rilpivirine | Small molecule | — | — |